Jing Hao, PhD, MD, MS, MPH
Dr. Hao’s research interests focus on economic evaluations of health services and programs which aim to improve patient outcomes through promoting personalized/precision healthcare. Specifically, in 3 sub-areas:
- Economic evaluation of genome sequencing and pharmacogenomics. Project examples include: MyCode return of results to patients and providers, Rational Integration of Clinical SEquencing (RISE), universal Lynch Syndrome screening, and HLA-B*1502 genotyping and carbamazepine induced side effects.
- Economic evaluation of risk-stratified disease prevention and treatment approach, e.g. cancer. Relevant projects include: new staging system of Squamous Cell Carcinomas of the Oropharynx, risk-prediction biomarker test which predicts progression risk of Barrett’s esophagus to esophageal adenocarcinoma, and new test which predicts risk of pre-eclampsia.
- Evaluation of clinical innovation programs focusing on medication adherence, healthcare utilization and costs.
The quantitative research methods she uses include decision analysis modeling and simulation, biostatistics and econometrics methods by utilizing electronic health records, claims data, both internal and national cost data sources and by systematic evidence synthesis.
- Guzauskas GF, Jiang S, Garbett S, Zhou Z, Spencer SJ, Snyder SR, Graves JA, Williams MS, Hao J, Peterson JF, Veenstra DL*. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States. Genet Med. 2022 Feb 25:S1098-3600(22)00033-8. doi: 10.1016/j.gim.2022.01.017. Epub ahead of print. PMID: 35227606.
- Hao J*, Hassen D, Gudgeon JM, Snyder SR, Hampel H, Williams MS, Sharaf RN, Lu CY, Williams JL, Schlieder V, Rahm AK. Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer. Journal of Personalized Medicine. 2021; 11(12):1284. https://doi.org/10.3390/jpm11121284
- Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, Hassen D, Snyder SR, Graves JA, Peterson JF, Williams MS, Veenstra DL*. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. JAMA Netw Open. 2020 Oct 1;3(10):e2022874. doi: 10.1001/jamanetworkopen.2020.22874. PMID: 33119106; PMCID: PMC7596578.
- Hao J*, Critchley-Thorne R, Diehl DL, Snyder SR. A Cost-Effectiveness Analysis of An Adenocarcinoma Risk Prediction Multi-Biomarker Assay For Patients With Barrett's Esophagus. Clinicoecon Outcomes Res. 2019 Oct 25;11:623-635. doi: 10.2147/CEOR.S221741. eCollection 2019. PubMed PMID: 31749626
- Snyder SR*, Hao J, Cavallari LH, Geng Z, Elsey A, Johnson JA, Mohamed Z, Chaiyakunapruk N, Chong HY, Dahlui M, Shabaruddin FH, Patrinos GP, Mitropoulou C, Williams MS. Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine. Public Health Genomics. 2018;21(5-6):217-227. doi: 10.1159/000500725. Epub 2019 Jun 12. PubMed PMID: 31189173; PubMed Central PMCID: PMC6762029.
EducationMD, Shanxi Medical University, 1999-2004
MS, Shanghai Jiaotong University School of Medicine, 2004-2007
MPH, University of Massachusetts Amherst, 2007-2009
PhD, University of Massachusetts Amherst, 2009-2015